


Immunogenicity and Safety of Shingrix in Adults Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine (Zoster-048 Study)

ACIP – June 21, 2017

Romulo Colindres, MD, MPH Global Medical Affairs Lead, Zoster GSK

Today's Presentation










- 1. Context and Rationale
- 2. Objectives and Study Design (Zoster-048)
- 3. Results (Zoster-048)
- 4. Summary

HZ/su Vaccine Composition

Context and rationale





^aQS-21 (Quillaja saponaria Molina, fraction 21; licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc, a Delaware, USA corporation). HZ/su, Herpes zoster subunit vaccine; MPL, monophosphoryl lipid A.

Zoster-048

Context and rationale



- Live-attenuated zoster vaccine (ZVL) has been licensed since 2006 and is recommended by ACIP for the prevention of HZ in immunocompetent adults ≥60 years of age
- − Approximately 31% of US adults \geq 60 years of age have been vaccinated for HZ¹
- Vaccination with ZVL as the current standard offers protection against HZ (VE=51% in adults ≥60 years of age)² and this protection wanes over time³
- The Zoster-048 study was designed to generate immunogenicity and safety data in persons who received ZVL at least 5 years prior, to help inform immunization policy decision-making

HZ, herpes zoster; VE, vaccine efficacy; ZVL, live-attenuated zoster vaccine (Zostavax[®]).

^{1.} CDC. Vaccination coverage among adults in the United States, NHIS, 2015. https://cdc.gov/vaccines. Accessed June 7, 2017.

^{2.} 2016 Zostavax PI. **3.** Morrison VA, et al. *Clin Infect Dis.* 2015;60:900-999.



Objectives and Study Design

Zoster-048

Brief Overview of Zoster-048

Prospective, group-matched, non-randomized trial



	Previous ZVL	No Previous ZVL				
Experimental design	Phase III, prospective, group-matched, non-randomized, open label, multicenter study in L					
HZ vaccination history	ZVL ≥5 years prior	No previous HZ vaccine				
Age range	≥65 years of age					
Co-primary objectives	 Compare anti-gE antibody concentrations 1 month post-dose 2 (non-inferiority)^a Safety and reactogenicity up to 1 month post dose 2 					
Secondary objectives	 Humoral immune response and cell-mediated immunity at baseline, 1 month post-dose 1, and 1 and 12 months post-dose 2 Safety up to 12 months post-dose 2 (ongoing) 					

^aNon-inferiority: upper limit of two-sided 95% CI of adjusted geometric mean concentration ratio (No Previous ZVL over Previous ZVL 1 month post-dose 2) is below 1.5 for anti-gE antibodies.

Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier;


No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax®).

CI, confidence internal; gE, glycoprotein E; HZ, herpes zoster.

Zoster-048 Study Design

Prospective, group-matched, non-randomized trial






Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]). HZ/su, Herpes zoster subunit vaccine; HI, humoral immune response; CMI, cell-mediated immunity.

Zoster-048 Participant Enrollment





Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]).



Results

Zoster-048; Active phase month 3 data

Summary of Demographic Characteristics



Total vaccinated cohort

		Previous ZVL n=215		No Previous ZVL n=215		Total N=430	
Characteristics	Parameters or Categories	Value or n	%	Value or n	%	Value or n	%
Age (years) at	Mean	71.1	-	70.8	-	70.9	-
vaccination dose 1	SD	4.5	-	4.6	-	4.6	-
	Median	70.0	-	70.0	-	70.0	-
	Minimum	65	-	65	-	65	-
	Maximum	87	-	85	-	87	-
Gender	Female	109	50.7	111	51.6	220	51.2
	Male	106	49.3	104	48.4	210	48.8
Geographic	White—Caucasian / European Heritage	215	100	215	100	430	100
Ancestry	Other	0	0.0	0	0.0	0	0.0
Time (years)	Mean	6.7	-	-	-	-	-
since previous ZVL vaccination	SD	1.11	-	-	-	-	-

Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier;

No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]).

SD, standard deviation.

Primary Endpoint Met

Non-inferiority of Previous ZVL to No Previous ZVL demonstrated for humoral immune response to HZ/su




Previous ZVL			No Previous ZVL			Adjusted GMC ratio (No Previous ZVL/ Previous ZVL)				
		95%	6 CI			95% CI		95% CI		6 CI
n	Adjusted GMC	LL	UL	n	Adjusted GMC	LL	UL	Value	LL	UL
204	48589.4	42649.4	55356.6	204	50522.9	44347.4	57558.4	1.04	0.92	1.17
Adjusted ratios of No Previous ZVL over Previous ZVL anti-gE antibody										
ELISA GMCs at one month post-dose 2 (ATP cohort for immunogenicity)					UL of 95% CI <1.5 Non inferiority is reached					

Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) \geq 5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]). ATP, according-to-protocol; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; gE, glycoprotein E; adjusted GMC, geometric mean antibody concentration adjusted for group-matching; HZ/su, herpes zoster subunit vaccine; LL, lower limit; UL, upper limit.

Month 3 Humoral Immune Responses Similar Between **Groups and Consistent With ZOE Trials**


Geometric mean concentrations of anti-gE antibody



Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]), gE, glycoprotein E; GMC, geometric mean concentration; M, month; ZOE-50/70, zoster efficacy trials.



Month 3 Cellular Immune Responses Similar Between Groups and Consistent With ZOE-50 Trial



ZOE-50 Zoster-048 Median (mean: 64.1 years of age) (mean: 70.9 years of age) gE-specific CD4+[2+] frequencies (log) Max 100000 2214 2312 427 425 1844 10000 90 Min 67 58 000000 00000 1000 333333 100 10 Pre-vaccination (M0) Post-dose 2 (M3) Pre-vaccination (M0) Post-dose 1 (M1) Post-dose 2 (M3) Previous ZVL No Previous 7VI HZ/su ZOE-50 in ≥50 years of age


Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) \geq 5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]). CD4+[2+], CD4+ T-cells secreting at least two activation markers (IFN- γ , IL-2, TNF- α , CD40L); gE, glycoprotein E; M, month; Q1, Quartile 1=25th percentile; Q3, Quartile 3=75th percentile; ZOE-50, zoster efficacy trial \geq 50 years of age.



Overview of Safety Reporting

Zoster-048 study ongoing; 3-month analysis






Safety Reporting up to 30 Days Post-Last Vaccination

Total vaccinated cohort



Percentage of subjects reporting an event from first vaccination up to 30 days post-last vaccination




No pIMDs or related SAEs were reported from first vaccination up to 30 days post last vaccination

^aAccording to the investigator AE is considered as potentially related to HZ/su vaccination.

Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) \geq 5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]). AE, adverse event; HZ/su, herpes zoster subunit vaccine; pIMD, potential Immune-Mediated disease; SAE, serious adverse event.

Solicited Local Symptoms Within 7 Days Post-Vaccination


Any grade overall by subject in total vaccinated cohort



Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]).

Solicited Local Symptoms Within 7 Days Post-Vaccination gsk

Grade 3 overall by subject in total vaccinated cohort



Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier;


No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax®).

^aRedness/swelling at the injection site scored as grade 3 for those >100 mm. Pain was scored as grade 3 if preventing normal activity.

Solicited Systemic Symptoms Within 7 Days Post Vaccination



Any grade overall by subject in total vaccinated cohort




Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) ≥5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]). ^aGastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain. ^b≥37.5°C (preferred route for recording temperature was oral).

Solicited Systemic Symptoms Within 7 Days Post-Vaccination



Grade 3 overall by subject in total vaccinated cohort



Previous ZVL, received live-attenuated zoster vaccine (Zostavax[®]) \geq 5 years earlier; No Previous ZVL, never received live-attenuated zoster vaccine (Zostavax[®]). ^aGastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain. ^bScored as grade 3 \geq 39°C (preferred route for recording temperature was oral). All other symptoms were scored as 3 for preventing normal activity.



Summary

Zoster-048: Active phase month 3 data

Zoster-048 Study Summary

Revaccination of previous ZVL recipients





Shingrix (adjuvanted herpes zoster subunit vaccine) induced a strong immune response (humoral and cellular), consistent with ZOE trials, regardless of previous vaccination with ZVL (live-attenuated herpes zoster vaccine)




No apparent safety differences observed between study groups within 30 days post dose 2 of Shingrix

Solicited local and systemic symptoms were similar between study groups

Summary of Shingrix Clinical Data

ZOE-50, ZOE-70, and Zoster-048



^aLarge safety database (>14,645 subjects) available to evaluate safety of HZ/su candidate vaccine (gE + $ASO1_B$) with more than 60,000 person years of active follow up.



Thank You